Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond

Medicinal Research Reviews

Volumn 21, Issue 6, 2001, Pages 540-552

  Jones, A Brian ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Fibrate; Glitazone; Nuclear hormone receptor; PPAR

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SCREENING; HYPERGLYCEMIA; MOUSE; NONHUMAN; RECEPTOR AFFINITY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0034798741     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.1025     Document Type: Conference Paper

References (60)

1. Nuclear receptors in metabolic diseases
2. Retinoid related molecules: New promises against lung and breast cancer
3. Novel ligands of steroid hormone receptors
4. Selective estrogen receptor modulators (SERMs) in clinical practice
5. The mechanism of action of thyroid hormones
6. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo
7. The nuclear hormone receptor gene superfamily
8. Coactivator and corepressor complexes in nuclear receptor function
9. The PPARs: From orphan receptors to drug discovery
10. PPARs: Insight into multiple cellular functions
11. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
12. Peroxisome proliferator-activated receptors in the cardiovascular system
13. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
14. Peroxisome proliferator-activated receptors: A family of lipid-activated transcription factors
15. The nuclear receptor PPARγ - Bigger than fat
16. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation
17. Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation
18. Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the PPAR family
19. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
20. The glitazone family of antidiabetic agents
21. Insulin sensitization in diabetic rat liver by an antihyperglycemic agent
22. Thiazolidinediones: A new class of antidiabetic drugs
23. PPARγ agonists: Therapeutic role in diabetes, inflammation and cancer
24. Troglitazone - A review of its use in the management of type 2 diabetes mellitus
25. Rosiglitazone in the treatment of Type 2 Diabetes Mellitus: A critical review
26. Pioglitazone
27. Synthetic ligands for PPAR gamma - Review of patent literature 1994-1999
28. Thiazolidinedione hepatotoxicity: A class effect?
29. Novel glucose-lowering non-thiazolidinedione hPPAR agonists
30. Novel PPARγ and PPARδ ligands produce distinct biological effects
31. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor
32. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
33. Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications
34. 12.14-protoglandin J2 is a ligand for the adipocyte determination factor PPARγ
35. Fatty acids and eicosanoids regulate gene expression through direct interactions with PPARs α and γ
36. Oxidized LDL Regulates macrophage gene expression through ligand activation of PPARγ
37. Indole acetic acids as novel PPARγ agonists
38. Differential activity of rosiglitazone enantiomers at PPARγ
39. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
40. Thiazolidinediones for type 2 diabetes - All glitazones may exacerbate heart failure
41. A pharmacological review of selective oestrogen receptor modulators
42. Fibrates, dyslipoproteinaemia and cardiovascular disease
43. Fibrates
44. Micronized fenofibrate: A new fibric acid hypolipidemic agent
45. PPARα receptors improve insulin sensitivity and reduce adiposity
46. Recent update on the PPAR alpha-null mouse
47. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes
48. A critical role for the peroxisome proliferator-activated receptor (PPAR) in the cellular fasting response: The PPAR-null mouse as a model of fatty acid oxidation disorders
49. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
50. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators
51. PPARα: Role in rodent liver cancer and species differences
52. A ureido-thioisobutyric acid (GW9578) is a subtype selective PPARα agonist with potent lipid lowering activity
53. A novel insulin sensitizer acts as a coligand for PPARα and PPARγ - Effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats
54. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
55. PPARδ functions as a prostacyclin receptor in blastocyst implantation
56. Member of the PPAR family of transcription factors is differentially expressed by oligodendrocytes
57. Activation of PPARδ alters lipid metabolism in db/db mice
58. Identification of PPAR ligands from a biased chemical library